• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    All News #Library

    Fresenius Kabi Issues Voluntary Nationwide Recall of Famotidine

    FDA

    Enforcement Report - Week of July 24, 2024

    FDA

    Enforcement Report - Week of January 25, 2023

    FDA

    Health Canada Issues Recall of Fresenius Kabi Canada Sodium Acetate Injection, USP: Particulate matter

    HEALTH CANADA

    Fresenius Kabi Issues Voluntary Recall of Sodium Acetate Injection, USP Due to the Presence of Particulate Matter

    FDA

    Enforcement Report - Week of October 6, 2021

    FDA

    Enforcement Report - Week of July 14, 2021

    FDA

    Fresenius Kabi Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection

    FDA

    Enforcement Report - Week of January 6, 2021

    FDA

    Enforcement Report - Week of December 30, 2020

    FDA

    Enforcement Report - Week of December 16, 2020

    FDA

    Enforcement Report - Week of December 2, 2020

    FDA

    Enforcement Report - Week of September 2, 2020

    FDA

    Enforcement Report - Week of July 22, 2020

    FDA

    Health Canada Issues Recall Fresenius Kabi Canada`s Dextrose 5% Injection

    FDA

    Enforcement Report - Week of June 17, 2020

    FDA

    Health Canada Isuues Recall of Fresenius Kabi Canada`s Penicillin G Sodium for Injection

    HEALTH CANADA

    Fresenius Kabi`s Recall of Ketorolac Results In QuVa Pharma® Recall of Compounded Sterile Product (R.E.C.K.)

    FDA

    Fresenius Kabi Issues Voluntary Nationwide Recall of 13 Lots of Ketorolac Tromethamine

    FDA

    Fresenius Kabi recalls Sodium Chloride Injection Due to Incorrect Labeling

    FDA

    Enforcement Report - Week of November 1, 2017

    FDA

    Enforcement Report - Week of April 19, 2017

    FDA

    Claris Confirms Patent Challenge for Generic Propofol in US

    THE ECONOMIC TIMES

    Fresenius Kabi USA, LLC Initiated a Class II Voluntary Recall of Midazolam Hydrochloride Injection Due to Lack of Assurance of Sterility

    Fresenius Kabi USA, LLC Initiated a Class II Voluntary Recall of Ondansetron Injection Due to Lack of Assurance of Sterility

    Fresenius Kabi USA, LLC Initiated a Class II Voluntary Recall of Cyanocobalamin Injection Due to Lack of Assurance of Sterility

    Fresenius Kabi USA, LLC Initiated a Class II Voluntary Recall of Gentamicin Injection Due to Defective Container

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.